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T cell epitopeFlaviviruses, such as dengue virus (DENV) and West Nile virus (WNV), are among the most prevalent human
disease-causing arboviruses world-wide. As they continue to expand their geographic range, multivalent ﬂavivi-
rus vaccines may become an important public health tool. Here we describe the immune kinetics of WNV DNA
vaccination and the identiﬁcation of a CD4epitope that increases heterologousﬂavivirus vaccine immunogenicity.
Lethal WNV challenge two days post-vaccination resulted in 90% protection with complete protection by four
days, andwas temporally associatedwith a rapid inﬂux of activated CD4 T cells. CD4 T cells fromWNVvaccinated
mice could be stimulated from epitopic regions in the envelope protein transmembrane domain. Incorporation of
this WNV epitope into DENV-2 DNA and virus-like particle vaccines signiﬁcantly increased neutralizing antibody
titers. Incorporating such potent epitopes into multivalent ﬂavivirus vaccines could improve their immunogenic-
ity and may help alleviate concerns of imbalanced immunity in multivalent vaccine approaches.
Published by Elsevier Inc.Introduction
Recent history has seen a global resurgence of arboviral diseases
once thought to be under control or those which have expanded
their geographic distribution and disease severity such as Japanese
encephalitis, tick-borne encephalitis and yellow fever, or West Nile
fever and dengue, respectively (Gubler, 2002). The recent autochtho-
nous transmission of DENV in KeyWest, Florida (CDC, 2010), a region
that has not seen local dengue transmission in the past 60 years,
raises awareness of the need for appropriate control measures for
these viruses. DENV, viscerotropic/hemorrhagic viruses that have
completely evolved to human hosts, exist as four closely related sero-
types (DENV-1, to -4), and WNV, an encephalitic virus maintained in
an enzootic mosquito–bird transmission cycle, are both single-
stranded RNA viruses in the Flavivirus genus. DENV disease is one of
the world's most important arboviral infections producing either a
mild dengue fever or severe, life-threatening dengue hemorrhagic
fever and shock syndrome (DHF/DSS). Severe DENV disease frequently
occurs in children residing in hyperendemic countries and is strongly
associated with secondary heterotypic infections (Sangkawibha et al.,
1984). WNV infection is often asymptomatic with approximately 24%
of patients developing West Nile fever, and 1 in 150 symptomatic pa-
tients developing meningitis or encephalitis (Ferguson et al., 2005).
With no DENV or WNV vaccines yet available on the market, vectorand Prevention, 3150 Rampart
.
nc.control and behavioral education programs are the only control
methods available to reduce their public health impact.
DNA vaccination is an active ﬁeld in vaccine technology following
the ﬁrst reports of plasmid DNA inducing an immune response to
plasmid-encoded antigens (Tang et al., 1992). Although DNA vaccines
are considered an important discovery in the ﬁeld of vaccinology
(Mor, 1998), they have been hampered by low immunogenicity and
efﬁcacy. Thus, various strategies to improve the immune response
by DNA vaccination have been developed. Earlier attempts to increase
DNA vaccine immunogenicity have included optimization of route,
dosage, and timing of administration; DNA encoded or exogenously
administered co-stimulatory molecules and cytokines; and differen-
tial prime-boost regimens (Leitner et al., 1999).
We have previously described the development and protective
efﬁcacy of a WNV DNA vaccine, pVWNi, directing the expression of
premembrane and envelope (prM/E) proteins that assemble to
form non-infectious viral-like particles (VLP) in vivo (Davis et al.,
2001). This DNA vaccine is highly immunogenic, a single intramus-
cular (i.m.) injection of pVWNi protected mice and horses from
WNV challenge (Davis et al., 2001). Additionally, pVWNi confers
protection in endangered California Condors (Chang et al., 2007)
and is safe and immunogenic in humans (Martin et al., 2007). In
this report, we describe the temporal kinetics of pVWNi immune
protection resulting in 90–100% protection from lethal challenge in
mice by 2–4 days post vaccination, respectively. In an attempt to un-
derstand this rapid protection and possibly improve the immunoge-
nicity of DENV vaccine candidates, we screened an overlapping
peptide library of the prM/E proteins of each vaccine to look for
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potent and promiscuous WNV CD4+ T cell epitope in the trans-
membrane domain of the WNV E protein. We introduce this T cell
epitope into DENV-2 DNA and VLP vaccines and demonstrate im-
proved immunogenicity of both vaccines through signiﬁcant in-
creases in neutralizing antibody responses. Thus, we have
identiﬁed a novel, promiscuous CD4+ T cell epitope from WNV
and present a strategy to introduce this epitope into heterologous
ﬂavivirus vaccines to increase their immunogenicity, an approach
which may have applications for multivalent ﬂavivirus vaccine
development.
Results
pVWNi vaccination elicits rapid protection from virus challenge
Previous studies have shown three weeks post vaccination (WPV)
with a single 100 μg injection of pVWNi, mice elicited high levels of
WNV neutralizing antibodies which protected 100% of mice from
WNV challenge (Davis et al., 2001). To understand the temporal ki-
netics of the immune response to pVWNi plasmid immunization
and to estimate the potential of using this vaccine as an emergency
counter measurement to reduce the impact of an ongoing epidemic,
C57BL/6 J mice were vaccinated with a single i.m. injection of 100 μg
of DNA, and challenged with 100,000 LD50 WNV (NY-99) at 1, 2, 4,
7, 14, or 21 days post vaccination (DPV) and compared to 1 and
21 days naïve age-matched controls. Surprisingly, 2 DPV 90% of
mice survived challenge (pb0.0001). All mice survived challenge by
4 DPV and beyond (pb0.0001) (Fig. 1), with the exception of the 7
DPV group (p=0.0004) where 2 mice succumbed to lethal disease.
These data suggest the pVWNi vaccine induces a rapid, protective im-
mune response.
Vaccination induces a rapid cellular inﬂux and activation
To investigate the causal nature of the rapid immune response and
protection elicited by pVWNi vaccination,we investigated the participa-
tion of cellular immunity in the early immune response. C57BL/6J mice
were vaccinated i.m. with pVWNi, pVax (vector only) and PBS as con-
trols. Fivemice per groupwere sacriﬁced at 2, 4, 7 and 14 DPV for histol-
ogy and ﬂow cytometry. Muscle from the vaccination site 4 and 7 DPV
was dissected and histology performed (Fig. 2A). Four DPV with
pVWNi, hematoxylin and eosin staining revealed a marked inﬁltration
of cells with lymphocytic and monocytic morphology around the injec-
tion site and 7 DPV the inﬁltrate hadmostly subsided. Mock vaccination
with PBS or pVax vector control did not show any cellular inﬁltration
suggesting pVWNi induced a transgene driven, transient cellular inﬁl-
tration at the injection site. Flow cytometric analysis of single cellFig. 1. pVWNi elicits rapid protection from WNV challenge. Kaplan–Meier survival of
C57BL/6 vaccinated mice (n=10) challenged at 1 (closed diamond), 2 (closed triangle
upright), 4 (closed circle), 7 (closed downward triangle), 14 (open square), or 21
(open diamond) days post vaccination i.p. with 100,000LD50 WNV NY99 compared to
the naïve 1 day post vaccination (closed square) and 21 days post vaccination (open
triangle) age-matched controls. *FRμNT50 values of pooled group sera.preparations from muscle tissue demonstrated a large proportion of
the cellular inﬁltrate 4 DPVwith pVWNiwas composed of F4/80+ anti-
gen presenting cells (APC), B220+ B cells, CD4+ and CD8+ T cells
(Fig. 2B). Antigen driven CD4+T cells accounted for signiﬁcantly higher
proportions of cellular inﬁltrate to the injection site than did CD8+ T
cells (p=0.008). Moreover, there was a larger proportion of activated
T cells (Fig. 2C) and APC (Fig. 2D) compared to the pVax control animals
(pb0.0001) suggesting the cellular activation was transgene speciﬁc.
Cytokine secretion by activated CD4+ T cells indicated Th1 and Th2 cy-
tokine production as early as 2 DPV for IL-2, IFNγ, TNFα, and IL-4, and by
4DPV for IL-5 (Fig. 3). IL-2 and TNFα remained elevated through the en-
tirety of the experiment while IFNγ and IL-4 subsided by 14 DPV. These
data suggest pVWNi vaccination induces both early Th1 and Th2 cyto-
kine proﬁles. Taken together, these data indicate the important role of
antigen activated CD4+ T cells and F4/80+ APC in the establishment
of the immune response to this vaccine.CD4 positive epitope present in transmembrane domain of WNV envelope
protein
The rapid immune response and protection elicited by the pVWNi
vaccine led us to ask if there might be differential T cell epitopes that
could explain some of the immunogenicity differences between the
pVWNi and our previously described DENV-2 DNA vaccine that ex-
presses DENV-2 prM, the 80% ectodomain of DENV-2 E, and the 20%
stem-anchor region of JEV E (Chang et al., 2003). The 20% JEV region
was shown to enhance VLP secretion and vaccine immunogenicity
compared to 100% DENV-2 E (Chang et al., 2003). Unlike the pVWNi
plasmid which only requires one 100 μg vaccination to protect 90%
of mice 2 DPV (Fig. 1), two vaccinations of 100 μg of DENV-2 plasmid
4 weeks apart were required to elicit sufﬁcient neutralizing antibody
to passively protect neonatal mice from DENV-2 challenge (Chang et
al., 2003). Although these viruses are very different in terms of their
pathogenesis, growth kinetics and immunogenicity, the differences
in immunogenicity between these vaccines is still remarkable despite
both containing identical transcriptional enhancer and promoter,
translational control element and JEV signal sequences for optimal
prM translocation (Chang et al., 2003). Based upon the above obser-
vations of the rapid cellular immune response toward pVWNi, we hy-
pothesized that differential CD4 T cell antigenic determinants might
be responsible for some of the immunogenicity differences between
the WNV and DENV-2 DNA vaccines (pVD2i).
To differentiate the cellular immune responses between pVWNi and
pVD2i, we constructed an overlapping peptide library covering the en-
tire prM and E protein coding sequences of each vaccine. We initially
screened the library using 23 pools of 10 15mer peptides. C57BL/6 J
mice (n=5) immunized with 100 μg of pVWNi or pVD2i were boosted
at three weeks and sacriﬁced at 6 weeks. Spleens were homogenized,
pooled, and the cells used to determine the positive peptide pools by
ﬂuorescence activated cell sorting analysis by intracellular cytokine
staining. Positive peptide pools were deconvoluted and individual pep-
tides were further tested in two independent experiments. Splenocytes
from vaccinated mice were incubated with 2 μg of each individual pep-
tide and stained for CD4 or CD8 and IFNγ. Positive peptides were com-
pared to identify peptides unique to pVWNi or signiﬁcantly different
from pVD2i. Interestingly, a strong CD4+ epitopic region was identiﬁed
in WNV E between amino acids 466–495 which was present, but much
weaker in the 20% JEV corresponding region of pVD2i (Fig. 4). Positive
peptides in pVWNi: TQGLLGALLLWMGIN,GALLLWMGINARDRS,WMGI-
NARDRSIALTF, and ARDRSIALTFLAVGG elicited 1.1, 2.5, 38.6, and 1.35%
CD4+/IFNγ+ T cells, respectively. While the similar peptide region in
pVD2i: QGLMGALLLWMGVNA, ALLLWMGVNARDRSI, MGVNARDRSIA-
LAFL, and RDRSIALAFLATGGV elicited 1.59, 3.17, 19.9, and 1.0% CD4+/
IFNγ+T cells, respectively. Although other peptides identiﬁed E protein
epitopes with similar immunogenicity for both pVWNi and pVD2i, this
Fig. 2. pVWNi elicits rapid cellular inﬂux to the injection site and antigen speciﬁc activation. Phenotypic analysis of cellular inﬁltrate recruited to injection site. (A) H&E staining of
cellular inﬁltration of dissected muscles from the injection site 4 and 7 days post vaccination with pVWNi, PBS or pVax (controls) at 600X magniﬁcation. H&E is representative of
n=5. Single cell suspensions were prepared from muscles and labeled with antibodies against extracellular markers. The small lymphocyte or CD3 population was gated for anal-
ysis. Percent positive are based on 106 total cells. (B) Phenotypic analysis of cells recruited to injection site 4 days post vaccination (striped histogram) compared to 0 days post
vaccination (dark histogram) Histogram is representative of n=5. (C) Analysis of activated (CD28+) CD4+ or CD8+ T cells at injection site 4 days post vaccination. (D) Analysis
of activated (CD80+) antigen presenting cells (F4/80+) or B cells (B220+) at injection site 4 days post vaccination. Data are expressed as mean+/−s.e.m. for n=5 and analyzed
with a Mann–Whitney Test. pb0.05 were considered signiﬁcant.
131H.R. Hughes et al. / Virology 424 (2012) 129–137region contained the only peptides differing dramatically between the
two vaccines.
This CD4 epitope ofWNVE protein is located in two transmembrane
domain (TMD) alpha helices. To our knowledge, this is the ﬁrst descrip-
tion of a CD4 T cell epitope present in this region of any ﬂavivirus E pro-
tein. The location of this CD4 T cell epitope could allow formanipulation
of the TMD in other ﬂavivirus vaccines since the TMD is either of low B
cell antigenicity or antigenically inert (Chang et al., 2003), B cell epi-
topes have not been identiﬁed in this region, and manipulation of this
region will not change VLP assembly, secretion or antigenic structure.
When comparing the transmembrane domains ofWNVE and JEV E pro-
teins, amino acid alignment revealed that the transmembrane domain
from amino acids 466–495 are entirely conserved with the exception
of four amino acids at 474, 484, 488, and 493 (Fig. 5). Using ProPed I
to predict CD8 epitopes and ProPed to predict CD4 epitopes, in silico
analysis revealed the transmembrane region of WNV, amino acids
466–501, contains promiscuous CD8 and CD4 epitopes with potential
to bind to several humanHLA alleles. Taken together, these data suggest
the incorporation of this epitope may increase the immunogenicity of
DENV-2 DNA vaccination in human populations.
Incorporation of WNV CD4 epitope into pVD2i increases immunogenicity
The identiﬁcation of a strong CD4 epitope in theWNV E TMD and its
potential as a promiscuous human CD4 and CD8 epitope led us to inves-
tigate if this epitope could be applied to increase the immunogenicity of
our DENV-2 DNA vaccine, pVD2i. Using site-directed mutagenesis wecreated a gain-of-function variant of the pVD2i vaccine. The four amino
acids at the C-terminal 20% JEV E in pVD2i were sequentially changed
to the corresponding amino acids in pVWNi. These changes produced
four plasmids designated pVD2iV474I (pVD2i-I), pVD2iV474I/A484T
(pVD2i-IT), pVD2iV474I/A484T/T488V (pVD2i-ITV), and pVD2iV474I/
A484T/T488V/V493L (pVD2i-ITVL). Toﬁrst conﬁrmdifferences in immu-
nogenicity of the WNV CD4 TMD epitope, we utilized C57BL/6J mice,
which were originally used to identify the CD4 epitope, immunized
with each construct, boosted on week-4 and sacriﬁced on week-8.
Focus reduction microneutralization (FRμNT50) was performed on indi-
vidual mouse sera (n=5) to assess immunogenicity between the con-
structs. Eight weeks post vaccination, pVD2i-I, the ﬁrst amino acid
change, did not signiﬁcantly increase the neutralizing antibody titer
(1:335) compared to pVD2i (1:261) (p=0.20) (Fig. 6A). However, vac-
cines containing the ﬁrst and second, ﬁrst second and third, or all four
WNV amino acids elicited increased levels of neutralizing antibody
(1:540, 1:434, and 1:501, respectively) with pVD2i-IT (p=0.02), and
pVD2i-ITVL (p=0.04) being signiﬁcant. This suggests amino acid 474 lo-
cated in the ﬁrst transmembrane helixmay not be an integral part of the
CD4 epitope as the subsequent amino acid substitutions at WNV E posi-
tions 484, 488, and 493, located in the second transmembrane helix, eli-
cited higher levels of neutralizing antibodies compared to pVD2i. The
presence of a trypsin cleavage site located between the ﬁrst and second
transmembrane helices which could cleave the transmembrane region
into two separate peptides also supports this ﬁnding.
Based upon the observation that the WNV CD4 epitope might act
as a potential promiscuous epitope and to generalize our ﬁndings,
Fig. 3. pVWNi vaccination elicits antigen speciﬁc Th1 and Th2 CD4 T cells. Splenocytes of
vaccinatedmicewereharvested 0, 2, 4, or 7 days post vaccination and stimulated for intra-
cellular cytokine staining. CD3+/CD4+ T cells were gated, 106 total cells were collected
and analyzed for the presence of Th1 (IL-2, IFNγ, or TNFα) or Th2 (IL-4 or IL-5) cytokines.
Data are expressed as mean+/−s.e.m. for n=5 and analyzed with Kruskall–Wallis and
Dunn's multiple comparison test. pb0.05 were considered signiﬁcant.
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100 μg of pVD2i or pVD2i-ITVL, boosted at 4 weeks, and sacriﬁced at
12 weeks. DENV-2 neutralizing antibody titers between the vaccines
at 4 WPV did not differ, 8 WPV there was a trend for increased neu-
tralization in the pVD2i-ITVL containing vaccine, and 12 WPV
pVD2i-ITVL elicited signiﬁcantly higher DENV-2 neutralizing anti-
body titers compared to pVD2i (p=0.03, Fig. 6B). This result demon-
strated that the addition of the WNV TMD CD4 epitope increased the
immunogenicity of pVD2i vaccine in an outbred population.
WNV CD4 epitope upregulates CD154 on CD4 T cells of pVD2i-ITVL
immunized mice
Cell to cell interactions play a pivotal role in regulating the im-
mune response. CD154 is expressed on a variety of cells (Grewal
and Flavell, 1998) and is the ligand for CD40, which is expressed on
B cells among others. Blocking the CD154 and CD40 interaction re-
veals a primary role of CD154 in regulating B cell proliferation, pro-
duction of immunoglobulin (Ig), and Ig class switching (Clark et al.,
1996). To better understand the mechanism of the observed antibody
increases we investigated the potential of the WNV TMD CD4 epitope
to increase the expression of CD154 on CD4 T cells. Swiss Webster
mice were chosen to simulate vaccination of an outbred population
and immunized with 100 μg of pVD2i, or pVD2i-ITVL on weeks
0 and 4. Five mice per group were sacriﬁced one WPV, and the
remaining 10 mice per group were sacriﬁced 12 WPV. Freshly har-
vested spleens were homogenized and stimulated for intracellular cy-
tokine staining. One WPV splenocytes from pVD2i-ITVL vaccinated
mice elicited signiﬁcantly higher levels of CD154 expressing T cells(p=0.016) compared to splenocytes from pVD2i vaccinated mice as
determined by a Mann Whitney test (Fig. 7A). In addition, stimulated
splenocytes 1 WPV elicited IL-4 positive and IFNγ positive CD4 T cells
suggesting the presence of both Th2 and Th1 driven T cell responses
(Fig. 7B, C). Twelve WPV, all stimulated splenocytes continue to
show both Th1 and Th2 driven T cell responses, though their magni-
tudes were greatly reduced compared to 1 WPV. Additionally, 12
WPV CD154 expression on CD4+ T cells was reduced and no differ-
ences remained between vaccine treatments (Fig. 7). These results
imply that when introduced into the pVD2i vaccine the WNV TMD
CD4 epitope functions early in the immune response to up regulate
CD154 on CD4 T cells, and that this early CD154 upregulation may
be the mechanism that produces the increased neutralizing antibody
titers and increased immunogenicity of this vaccine modiﬁcation.
However, how this early increase in CD154 translates to increased
neutralizing antibody titers between 8 and 12 weeks post vaccination
remains unclear.
WNV CD4 epitope also increases immunogenicity of DENV VLP vaccine
Immunogenic proteins encoding neutralizing epitopes are a com-
monly used platform to stimulate protective immunity against many
pathogens. To investigate the beneﬁt of adding the WNV TMD CD4
epitope to protein based vaccine formats, we immunized Swiss Web-
ster mice (n=5) with 1 μg of puriﬁed pVD2i or pVD2i-ITVL derived
VLPs. All VLP vaccines were formulated with 8% Alum, boosted at
4 weeks and sacriﬁced at 8 weeks. The neutralizing antibody titer of
pVD2i-ITVL VLP (p=0.02) was signiﬁcantly increased compared to
the pVD2i VLP vaccine (Fig. 8). These results were qualitatively similar
to those observed for the DENV-2 DNA vaccines (Fig. 6) and suggest
that the incorporation of the WNV TMD CD4 epitope can increase vac-
cine immunogenicity for protein based vaccines in addition to DNA vac-
cine formats.
Discussion
We initially investigated the temporal kinetics of protection from
WNV vaccination with the DNA vaccine pVWNi. Our data indicates
that by 2 DPV 90% of mice were protected from lethal WNV chal-
lenge, 100% protection was achieved by 4 DPV, and that this acceler-
ated protection was temporally correlated with the rapid inﬂux and
activation of immune cells to the injection site. Transmission of WNV
through blood and organ transplantation is well documented
(2002a; 2002b; 2002c). Central nervous system involvement in
WNV infection is common in immunocompromised hosts such as el-
derly and transplant patients. Community-acquired WNV infection
has been reported following solid organ transplantation ranging
from 2 months to 8 years posttransplant (Armali et al., 2003;
Barshes et al., 2006; DeSalvo et al., 2004; Kumar et al., 2004). More-
over, transplant recipients appear more likely to develop severe neuro-
logical symptoms and perhaps death, following WNV infection
compared to immunocompetent hosts (Kleinschmidt-DeMasters et al.,
2004; Kumar et al., 2004). Our observations of the rapid protection in-
duced by pVWNi and the non-infectious nature of this vaccine offer a
unique target demographic for vaccination. The possibility of vaccinat-
ing transplant patients pretransplant or the high risk elderly population
with prophylactic vaccination is an attractive avenue deserving further
attention. Additionally, the rapid protective immunity induced by our
vaccine supports the possibility of using this vaccine as an emergency
counter measurement to reduce the impact of imminent or ongoing
outbreaks in these high risk populations.
Several T cell epitopes have been described for the ﬂaviviruses,
many of which are localized to the non-structural proteins while
fewer eptiopes have been identiﬁed in the E protein (Rothman et
al., 1996; Weiskopf et al., 2011). We have identiﬁed a potent CD4 T
cell epitope in the transmembrane domain region of WNV E protein,
Fig. 4. WNV transmembrane domain region contains a strong CD4 epitope not present in JEV. Splenocytes from mice (n=5) vaccinated on 0 and 3 weeks with 100 μg pVWNi or
pVD2i (containing C terminal 20% JEV E (Chang et al., 2003)) were stimulated ex vivo with 2 μg of envelope peptide. Cells were stained for CD3, CD4 and IFNγ and 10,000 of the CD3/
CD4 gated populationwas counted.While both pVWNi-WMGINARDRSIALTF and pVD2i-MGVNARDRSIALAFL elicited IFNγ producing CD4 T cells, the response to pVWNiwas greater than
that of pVD2i. Dot plots are representative of a single experiment.
133H.R. Hughes et al. / Virology 424 (2012) 129–137and a much weaker CD4 T cell epitope in the corresponding 20% JEV
region of our DENV-2 DNA vaccine. Consistent with our ﬁndings, a
portion of this epitopic region, amino acids 481–495, has been
shown to contain a potent WNV CD8 T cell epitope with protective
cytotoxic capabilities (Brien et al., 2007). The ﬂavivirus transmem-
brane domain is variable between serocomplexes yet conserved
within members of the same serocomplex, suggesting potential dif-
ferential T cell antigenicity across the ﬂaviviruses. The effect of suchdifferential antigenicity of the transmembrane domain on immuno-
genicity and virulence between the ﬂaviviruses is currently being in-
vestigated in our lab.
Adjuvant discovery has been an active area of investigation be-
cause many non-replicating vaccine candidates are hindered by low
immunogenicity and efﬁcacy. Incorporation of the WNV TMD CD4
epitope signiﬁcantly increased the immunogenicity of both pVD2i
DNA and VLP vaccines. Previous attempts to increase the
Fig. 5. The transmembrane domain region is well conserved between WNV and JEV. Single letter amino acid abbreviations are shown for the transmembrane domain of WNV E
protein using WNV numbering. Amino acids conserved relative to WNV in the other viruses are shown as dots, and single letter abbreviations for non-conserved amino acids
are depicted. Four amino acids differ between residues 466 and 495 of WNV and JEV and are highlighted green.
134 H.R. Hughes et al. / Virology 424 (2012) 129–137immunogenicity of DNA vaccination have included the use of genetic
adjuvants where immunostimulatory molecules are encoded in the
DNA vaccine, such as CpG motifs, cytokines, chemokines, GM-CSF,
and ubiquitin (Chiarella et al., 2008), however, long-term effects of
constitutive production of such immune stimulatory molecules are
unknown and still under review in clinical trials. Additional epitope
adjuvants have been described using universal T cell epitopes such
as tetanus toxin (King et al., 1998; Zhu et al., 2008), pan DR epitope
(PADRE) (del Guercio et al., 1997), hepatitis B small surface antigen
(Chen et al., 2010), and heat-shock protein 70 (Lu et al., 2009). How-
ever, with the usage of tetanus toxin, hepatitis B and heat-shock pro-
tein 70, the development of anti-carrier immunity hindering
vaccination or concurrent booster vaccinations is a possible concern.Fig. 6. The incorporation of the WNV TMD CD4 epitope increases the immunogenicity
of DENV-2 DNA vaccines. (A) FRμNT50 DENV-2 neutralizing antibody (Nt. Ab.) titers of
C57BL/6 mice vaccinated twice with 100 μg pVD2i containing successive TMD modi-
ﬁcations 8 WPV. Data are expressed as mean+/− s.e.m for n=5. A non-parametric
Kruskall–Wallis and Dunn's multiple comparison test was used to compare vaccine
treatments. pb0.05 were considered signiﬁcant. (B) FRμNT50 DENV-2 Nt. Ab. titers
of Swiss Webster mice vaccinated twice with 100 μg of pVD2i or pVD2i-ITVL 4, 8,
and 12 WPV. Data are expressed as mean+/− s.e.m. for n=10. A non-parametric
one-tailed Mann–Whitney Test was used to compare vaccine treatments. pb0.05
were considered signiﬁcant.Incorporating a naturally occurring WNV CD4 epitope into heter-
ologous ﬂavivirus vaccines offers advantages over these other genetic
adjuvants in improving ﬂavivirus vaccination formulation. There is
limited concern of existing immunity toward the WNV TMD CD4 epi-
tope from previous exposure interfering with the vaccine efﬁcacy.
The transmembrane domain of ﬂaviviruses is either of low B cell an-
tigenicity or antigenically inert, (Chang et al., 2003) and no B cell epi-
topes have been identiﬁed in this region. Additionally, differential T
cell antigenicity between the ﬂaviviruses can be readily manipulated,
as demonstrated in this study. With the global resurgence and expan-
sion of ﬂavivirus disease, there is an increasing demand and utility for
multivalent ﬂavivirus vaccines beyond the generally accepted neces-
sity of tetravalent DENV vaccines. Multivalent vaccine interference
is a frequently observed phenomenon (Dagan et al., 2010; Guy et
al., 2009). The incorporation of this naturally occurring immunodomi-
nant ﬂavivirus epitope into live attenuated DENV vaccines could help
alleviate observations of serotype-speciﬁc interference (Guy et al.,
2009) and induce a more balanced immune response. We are currently
examining the use of this WNV epitope to balance the immunogenicity
of tetravalent DENV vaccines and its application to multivalent ﬂavivi-
rus vaccines beyond DENV deserves further investigation.
The identiﬁcation of naturally occurring dominant CD4 epitopes in
one component of a multivalent vaccine and the incorporation of this
CD4 epitope to increase vaccine immunogenicity of a weaker compo-
nent as demonstrated in this study may be a possible generalized
strategy for multivalent vaccines hindered by imbalanced immunoge-
nicity or interference. For example, serotype speciﬁc immune inter-
ference affecting immunogenicity of multivalent human papilloma
virus (HPV) VLP vaccine was recently demonstrated (Zhang et al.,
2010). Licensed tetravalent vaccine containing VLP for HPV serotypes
16/18/6/11 elicited a balanced serotype speciﬁc neutralizing antibody
response, while the trivalent HPV 16/18/58 displayed signiﬁcant de-
creases in type speciﬁc neutralizing antibodies to serotype 58. Identi-
fying and manipulating different immunogenic elements such as the
CD4 T cell epitope identiﬁed here could prove a strategy to under-
standing and alleviating the antigenic differences between virus sero-
types interfering with multivalent vaccine safety and efﬁcacy.
Materials and methods
Vaccines
Construction and characterization of pVWNi and pVD2i DENV-2 DNA
plasmid optimized with C terminal 20% JEV have been previously de-
scribed (Chang et al., 2007; Chang et al., 2003; Davis et al., 2001).
pVWNi and pVD2i were manufactured by Aldevron (Fargo, ND). pVD2i
with substitutions in the TMD, pVD2iV474I, pVD2iV474I/A484T,
pVD2iV474I/A484T/T488V, and pVD2iV474I/A484T/T488V/V493L, were
generated by using Quick change site-directed mutagenesis kit (Strata-
gene) with the following primers (Operon): 3′CGGGATGACGAGACC-
TACCCGTATTTGCGTGCTCTG5′, 3′GCTAGTTACGAAACTGGAAGAATCGGT
GTCCCCCACAC5′, 3′CTGGAAGAATCGGCATCCCCCACACGAGCACAAG5′,
and 3′CCCCCACACGAGGACAAGAATCGCTGGTTACACG5′. These were
Fig. 7.WNV TMD CD4 epitope induces early CD154 expression on CD4 T cells. Splenocytes from vaccinated mice were stimulated ex vivo with UV inactivated DENV-2. The CD3+/
CD4+ T cell population was gated and 40,000 gated events were analyzed. (A) CD154 expression of Swiss Webster CD4 T cells one and 12 WPV. (B) Th2 driven T cell responses of
Swiss Webster mice one and 12 WPV. (C) Th1 driven T cell responses of Swiss Webster mice one and 12 weeks pv. (D,E,F) Representative dots plots from CD4+ T cells expressing
(D) CD154, (E) IL-4, or (F) IFNγ 1 week pv from one individual, either naïve splenocytes stimulated with media (left, negative control) or pVD2i-ITVL immunized individual stim-
ulated with DENV-2 (right). The percentages from the negative control were subtracted from the DENV-2 stimulated samples before analysis (see Materials and methods). Data are
expressed as mean+/−s.e.m. for n=5 (1 week pv) or n=10 (12 weeks pv). A non-parametric one-tailed Mann–Whitney test was used to compare vaccine treatments. pb0.05
were considered signiﬁcant.
135H.R. Hughes et al. / Virology 424 (2012) 129–137grown in E. coli XL1 Blue cells and DNA puriﬁed by Endofree Plasmid
Maxi-prep Kit (Qiagen) as per manufacturer's instructions. Structural
gene elements and regulatory elements of all plasmids were sequenced
entirely using a Beckman Coulter CEQ 8000 genetic analysis system
(Beckman Coulter) and analyzed by Beckman Coulter CEQ 8000
(Beckman Coulter) and Lasergene software (DNASTAR). Virus-likeFig. 8. WNV TMD CD4 epitope increases immunogenicity of DENV-2 VLP vaccines.
FRμNT50 DENV-2 Nt. Ab. titers of Swiss Webster mice vaccinated with 1 μg of VLP. Data
are expressed as mean+/−s.e.m. for n=5. A non-parametric one-tailed Mann–Whitney
test was used to compare vaccine treatments, pb0.05 were considered signiﬁcant.particles (VLPs)were generated by transformation of COS-1 cells as pre-
viously described (Chang et al., 2000) and secreted VLPswere harvested
from serum and animal product free media, Sfm4megavir (Hyclone).
Tissue culture media was harvested, pelleted by ultracentrifugation at
19,000 rpm, concentrated 100-fold in TNbuffer, pelleted by 20% sucrose
cushion, and resuspended in 1/100 of original volume in TN buffer. Pro-
tein concentration was determined by Bradford Assay (BioRad) as per
manufacturer's instructions. VLP vaccines consisted of 1 μg protein in
8% Alum (Thermo Scientiﬁc).
Mice
C57BL/6Jmice (H-2b)were purchased from Jackson Laboratory. Swiss
Webster mice were purchased from Charles River. All mice were immu-
nized i.m. with 100 μg of DNA or 1 μg of VLPs formulated with 8% Alum.
C57BL/6 mice were immunized with pVWNi on day 0 and challenged
with 100,000 LD50 WNV NY99 i.p. on 1, 2, 4, 7, 14, or 21 DPV (n=10).
C57BL/6 mice were immunized with pVWNi on day 0 and sacriﬁced on
2, 4, 7, and 14 DPV (n=5), muscles, inguinal lymph nodes and spleens
collected. C57BL/6J mice (n=5) were immunized with pVWNi or
pVD2i on weeks 0 and 3, sacriﬁced and splenectomized on week 6.
C57BL/6J mice (n=5) were immunized with pVD2i TMD constructs at
136 H.R. Hughes et al. / Virology 424 (2012) 129–137weeks 0 and4, sacriﬁced onweek8, splenectomized and serumcollected.
Swiss Webster mice (n=10) were similarly immunized and sacriﬁced
on week 12, splenectomized and serum collected. Swiss Webster mice
(n=5) were immunized with 1 μg VLP on weeks 0 and 4, sacriﬁced on
week 8, splenectomized and serum collected. Animal experiments were
approved by IACUC.
Histology
Mice were euthanized on 4 and 7 DPV and the tibialis muscle re-
moved, ﬁxed in 4% buffered formalin solution and sent to Colorado
State University Diagnostic Laboratories for slide preparation and
Hematoxylin and Eosin staining. Slides were viewed on a Zeiss mi-
croscope, at 600× magniﬁcation.
Peptide scanning library
A library of 15 amino acid peptides with 10 amino acid overlaps
was designed to cover either the envelope (E) protein or the pre-
membrane (prM) region of WNV or DENV-2 (AC Scientiﬁc, Inc.). Pep-
tides were arranged in pools as described previously (Betts et al.,
2001; Hoffmeister et al., 2003; Kern et al., 2000; Maecker et al.,
2001). Single peptides were used at a concentration of 1 μg/ml with
the total concentration of each pool being no greater than 10 μg/ml
(Betts et al., 2001; Kern et al., 2000; Maecker et al., 2001). Pool vol-
umes were diluted in such a manner that the DMSO concentration
is no greater than 1% of v/v (Hoffmeister et al., 2003). Individual pep-
tides were identiﬁed by pool overlap. The selected peptides went
through a second round of screening. Positive peptides were deter-
mined by ex vivo stimulation of vaccinated splenocytes and demon-
strated CD4+ and IFN-γ expression.
Epitope prediction of positive peptides was accomplished using on-
line engines ProPedI (http://www.imtech.res.in/raghava/propred1/)
and ProPed (http://www.imtech.res.in/raghava/propred/) setting the
threshold to 1%.
Intracellular cytokine staining
Single cell suspensions were made from freshly harvested C57BL/6J
or Swiss Webster spleens and plated in 96-well plates for extracellular
surface antigen and intracellular cytokine staining. Splenocytes were
stimulated with peptides as described above or 2 μg of UV inactivated
DENV or rWNV-E (expressed in Drosophila melanogaster S2 cells gener-
ously donated by Tian Wang); PHA (Roche Diagnostics) was used as a
positive control, and naïve splenocytes in cell culture medium as nega-
tive controls. 96-well plates were incubated 2 h and 1 μg of Golgi plug
(BD Biosciences) was added to each well, incubated an additional 4 h
before extracellular and intracellular staining.
Flow cytometry
The antibodies mouse BD Fc block, CD3, CD4, CD8, CD11b, F4/80,
CD19, B220, CD80, CD28, CD154, IFNγ, TNFα, IL-2, IL-4, and IL-5
were purchased from BD Biosciences or eBiosciences. Stimulated
splenocytes or single cell preparations of muscle cells were centri-
fuged, washed with BD Stain buffer (BD Biosciences), Fc blocked,
and labeled for extracellular antigens: CD3, CD4, CD8, CD11b, F4/80,
CD19, B220, CD80, CD28, or CD154. For intracellular staining CD3+/
CD4+ splenocytes were then ﬁxed with BD cytoﬁx/cytoperm buffer
(BD Biosciences) and labeled for IFNγ, TNFα, IL-2, IL-4, or IL-5. For
WNV and peptide library work, cells were analyzed using a High Per-
formance MoFlo Cell Cytometer/Sorter and Summit version 3 soft-
ware (DakoCytomation). Cells were gated on the small lymphocyte
or CD3 positive population and 10,000 events were collected. For
transmembrane domain replacement studies, ﬂuorescence was
detected with BD FACS Calibur and Cell quest software (BDBiosciences). The lymphocyte population was gated on a FSC and
SSC plot and further gated on CD3+/CD4+, 40,000 gated events were
collected and analyzed for FITC and PE positive cells. Double-positive
cells from the negative control were subtracted from each sample be-
fore statistical analysis. Dot plots are representative of a single replicate.
Neutralization assay
A focus reduction microneutralization (FRμNT) technique was uti-
lized as previously described (Crill et al., 2009) with few modiﬁca-
tions. Vaccinated mouse sera were diluted 1:10, heat inactivated,
titrated 2-fold to the volume of 40 μL, and 320 virus FFU/40 μL were
added to each dilution. Virus strains WNV NY-99 and DENV-2 16681
were used in neutralization assays. FRμNT titers were calculated for
each virus relative to a back titration. Exact FRμNT titers were modeled
by the sigmoidal dose–response with variable slope using Graph Pad
Prism version 4. Values are the average of two independent replicates.
Statistical analysis
All graphed original values are means+/−s.e.m. Data were com-
pared using non-parametric Mann–Whitney or Kruskall–Wallis test.
Survival data was analyzed using Kaplan–Meier survival curves. Sta-
tistical analysis performed with SAS 9.2. pb0.05 were considered
signiﬁcant.
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